secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcellx, Inc. (ACLX)
CIK:        0001786205
Form:       8-K
Filed at:   2022-05-12T23:59:59+00:00
Accession:  0001193125-22-148651
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcellx Q1 net loss $32.4M; CART-ddBCMA 100% ORR; doses first ACLX-001 patient
------------------------------------------------------------------------------

- Q1 net loss $32.4M (vs $11.3M Q1 2021); R&D expense $24.4M (+$15.9M).
- Cash and marketable securities $210.9M as of Mar 31; funds operations into H2 2023.
- First patient dosed in Phase 1 of ACLX-001 (ARC-SparX) for relapsed/refractory multiple myeloma.
- CART-ddBCMA Phase 1 data published in Blood Advances: 100% ORR, 75% CR/sCR.
- CART-ddBCMA oral abstract at ASCO June 5; data on ~25 patients to be presented.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1786205/000119312522148651/0001193125-22-148651-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1786205/000119312522148651/d338467d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-148651

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer